Multiple Myeloma in Relapse Clinical Trials

90 clinical trials for Multiple Myeloma in Relapse across international registries, including 24 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE2
• Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) — RECRUITING · PHASE1
• A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma — RECRUITING · PHASE1
• CAR-T in Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma — RECRUITING · PHASE1
• HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM — RECRUITING · PHASE2
• Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma — RECRUITING · PHASE1
• Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse — RECRUITING · PHASE2
• Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma — RECRUITING · NA
• Universal CAR-T Cell Therapy for MM — RECRUITING · NA
• BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma — RECRUITING · PHASE1
• A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies — RECRUITING · PHASE1
• Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma — RECRUITING · PHASE1
• Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma. — RECRUITING
• a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease — RECRUITING · PHASE1
• BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease — RECRUITING · PHASE1
• All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma — RECRUITING · PHASE2
• A Trial of Selinexor, Ruxolitinib and Methylprednisolone — RECRUITING · PHASE1
• A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• LMY-920 for Treatment of Relapsed or Refractory Myeloma — RECRUITING · PHASE1
• BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma — RECRUITING · PHASE1
• CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies — RECRUITING · PHASE1
• Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib — ACTIVE_NOT_RECRUITING · PHASE2
• TriPRIL CAR T Cells in Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
• Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM — ACTIVE_NOT_RECRUITING · PHASE2
• Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma — NOT_YET_RECRUITING · PHASE4
• Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes — ACTIVE_NOT_RECRUITING · PHASE2
• Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma — NOT_YET_RECRUITING · PHASE1
• UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma — WITHDRAWN · PHASE1
• Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• Ixazomib + Pomalidomide + Dexamethasone In MM — ACTIVE_NOT_RECRUITING · PHASE1
• Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. — NOT_YET_RECRUITING · PHASE1
• Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma — COMPLETED · PHASE1
• Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse — TERMINATED · NA
• Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) — ACTIVE_NOT_RECRUITING · PHASE1
• Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients — COMPLETED
• Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma — ACTIVE_NOT_RECRUITING
• Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells — COMPLETED · PHASE1
• A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma — TERMINATED · PHASE1
• TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma — COMPLETED · PHASE2
• Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study — COMPLETED · PHASE4
• Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma — NOT_YET_RECRUITING · PHASE2
• A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors — WITHDRAWN · PHASE1
• Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies — TERMINATED · PHASE2
• Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE3
• Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs — WITHDRAWN

Refine this search